Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

A Novel Variant, NDM-5, of the New Delhi Metallo-β-Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom

Michael Hornsey, Lynette Phee, David W. Wareham
Michael Hornsey
1Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynette Phee
2Division of Infection, Barts & The London NHS Trust, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Wareham
1Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom
2Division of Infection, Barts & The London NHS Trust, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: d.w.wareham@qmul.ac.uk
DOI: 10.1128/AAC.05108-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A new variant of the New Delhi metallo-enzyme (NDM) carbapenemase was identified in a multidrug-resistant Escherichia coli ST648 isolate recovered from the perineum and throat of a patient in the United Kingdom with a recent history of hospitalization in India. NDM-5 differed from existing enzymes due to substitutions at positions 88 (Val→Leu) and 154 (Met→Leu) and reduced the susceptibility of E. coli TOP10 transformants to expanded-spectrum cephalosporins and carbapenems when expressed under its native promoter.

TEXT

The treatment of Gram-negative infections is increasingly complicated by the emergence of antimicrobial resistance. The recent identification of a new β-lactamase, New Delhi metallo-enzyme (NDM), able to confer resistance to all β-lactams with the exception of aztreonam (12) has been met with considerable alarm. The rapid spread of NDM-producing strains across the globe and the dissemination of the gene into multiple Gram-negative species via multidrug resistance (MDR) plasmids has raised serious concerns that common infections with these organisms may soon be untreatable (11). In this report, we describe the first detection of a new sequence variant of the NDM enzyme in an MDR strain of Escherichia coli, designated EC405, recovered from a patient in the United Kingdom.

EC405 was isolated from a 41-year-old patient transferred directly to our institution after a 6-week stay in a medical center in Goa, India. The patient was initially admitted with herpes simplex encephalitis and treated with acyclovir but was repatriated to the United Kingdom following neurological deterioration.

EC405 was recovered from routine screening swabs (perineum and throat) plated directly onto CHROMagar KPC, a medium selective for the growth of carbapenem-resistant Enterobacteriaceae (9). The isolate was confirmed as E. coli by API 20E (bioMérieux, Marcy l'Étoile, France) and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker UK Ltd., Coventry, United Kingdom). Susceptibility testing was performed using the MicroScan WalkAway Negative Combo 36 panel (Siemens Healthcare Diagnostics, Deerfield, IL) and the Etest method (bioMérieux) for susceptibility to colistin and tigecycline. Resistance was defined according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Enterobacteriaceae breakpoints (EUCAST) were used in the case of tigecycline.

The isolate was resistant to all cephalosporins (cefuroxime, ceftriaxone, cefotaxime [CTX], cefoxitin [FOX], ceftazidime [CAZ], cefepime; MIC, >32 μg/ml), carbapenems (ertapenem [ERT], imipenem [IMP], meropenem [MEM]; MIC, >8 μg/ml), aminoglycosides (gentamicin, tobramycin, amikacin; MIC, >32 μg/ml), and quinolones (ciprofloxacin: MIC, >2 μg/ml) tested but susceptible to colistin (MIC, 0.19 μg/ml) and tigecycline (MIC, 0.38 μg/ml). A modified Hodge test using ERT (10 μg) as the indicator disc and comparison of zone sizes surrounding IMP discs supplemented with and without 750 μg EDTA suggested the production of a metallo-carbapenemase (6).

A number of multiplex PCRs (3, 4) were used to identify genes encoding blaTEM and blaCTX-M1-like extended-spectrum β-lactamases (ESBLs). Sequencing of these amplicons revealed that they encoded TEM-1 and CTX-M-15 β-lactamases. No blaSHV, blaOXA, blaPER, blaVEB, blaKPC, blaGES, blaIMP, blaVIM, blaSIM, blaGIM, blaSPM, or plasmidic AmpC-like genes were detected, but the entire open reading frame of blaNDM was successfully amplified using the following primers: NDM-Full F, 5′ ATG GAA TTG CCC AAT ATT ATG CAC; NDM-Full R, 5′ TCA GCG CAG CTT GTC GGC. Purified amplicons were ligated into pCR2.1 and the expression vector pBAD (Invitrogen, Paisley, United Kingdom) and transformed in E. coli TOP10 (Invitrogen). Plasmids (pCR2.1 NDM-5 and pBAD NDM-5) were extracted, and the blaNDM allele was sequenced multiple times on both strands using a combination of the amplification and vector-specific (M13) primers with an ABI 3730xl DNA analyzer (Applied Biosystems, Warrington, United Kingdom). All sequencing was performed at Source BioSciences Ltd. (Cambridge, United Kingdom). Chromatograms were analyzed and consensus sequences aligned using BioEdit software version 7.0.9.0. Analysis of the predicted amino acid sequence revealed two substitutions at positions 88 (Val→Leu) and 154 (Met→Leu) relative to the NDM-1 (accession no. FN396876) and NDM-2 (accession no. AEA41876) peptide sequences available in GenBank. The point mutations at positions 262 (G →T) and 460 (A →C) responsible for the amino acid substitutions were confirmed by reamplification and sequencing of the gene from a fresh EC405 DNA preparation. The new enzyme variant was designated NDM-5 by the curators of the Lahey database of β-lactamases (http://www.lahey.org/Studies/webt.asp) and deposited in GenBank under the accession number JN104597.

Primers external to the blaNDM-5 coding sequence were used to amplify the gene along with its native promoter using primers and conditions previously described (5). These amplicons were also cloned in pCR2.1 and pBAD TOPO, generating plasmids pCR2.1P+NDM-5 and pBADP+NDM-5, which were then transformed into E. coli TOP10.

The MICs of a range of β-lactams for E. coli TOP10 transformants were determined by Etest on Mueller-Hinton (MH) agar. The medium was supplemented with arabinose (0.0002 to 0.2%) and glucose (0.2%) for the transformant harboring pBAD NDM-5. Cephalosporin, aztreonam, and carbapenem (ERT, IMP, and MEM) MICs for transformants carrying blaNDM-5 expressed constitutively from the pCR2.1 lac promoter, inducibly when under the control of the araBAD promoter in pBAD, and under the control of the NDM-5 native promoter are shown in Tables 1 and 2. Interestingly, expression in TOP10 from either plac or paraBAD had only limited effects on the susceptibility of the TOP10 transformants to carbapenems. Only when the native promoter was used were marked increases in the carbapenem MICs observed (Table 1). As a comparator, blaNDM-1 with and without the same promoter region was also cloned in the E. coli TOP10 background. The effects of NDM-5 on the susceptibility of E. coli to carbapenems as well as expanded-spectrum cephalosporins appeared to be greater than those of NDM-1 (Table 1). Whether the amino acid substitutions unique to NDM-5 could enhance the hydrolytic activity of the enzyme and be responsible for the differences observed will need to be assessed in kinetic studies using the purified enzyme.

View this table:
  • View inline
  • View popup
Table 1.

Antibiotic susceptibilities of E. coli strains and transformants used

View this table:
  • View inline
  • View popup
Table 2.

Susceptibility of E. coli TOP10 transformants following inducible expression of NDM-5 from the paraBAD promoter

Additional molecular analyses were undertaken to further characterize strain EC405. Phylotyping using a multiplex PCR method (2) defined it as a member of phylogroup D. Analysis of the region upstream of the blaNDM-5 allele revealed the presence of part of ISAba125, likely derived from Acinetobacter baumannii, creating a hybrid (−35/−10) promoter exactly as in an NDM-1-producing E. coli isolate described by Poirel et al. (8). Multilocus sequence typing performed according to the protocol available at http://mlst.ucc.ie/mlst/dbs/Ecoli/documents /primersColi_html identified the isolate as a member of sequence type 648 (ST648). This ST has been shown to cause a significant proportion of ESBL-producing E. coli bacteremias in a series reported from the Rotterdam area of the Netherlands (10). In another recent study, three isolates of ST648 were shown to harbor NDM, two of which were recovered from patients hospitalized in Karachi, Pakistan, while the other was isolated from a patient in the United Kingdom (7).

Plasmids carried by EC405 were extracted using a Qiagen miniprep kit (Qiagen, Crawley, United Kingdom) and separated by agarose gel electrophoresis. The NDM-5 gene was localized to a plasmid of >100 kb by PCR using gel-purified plasmid DNA as the template and Southern hybridization with a digoxigenin-labeled (Roche, Burgess Hill, United Kingdom) blaNDM-specific probe. PCR replicon typing (1) revealed that the plasmid encoding NDM-5 belonged to the incF incompatibility group. Other resistance determinants detected included aadA5 and dfrA17 genes located within a class I integron structure and the 16S rRNA methylase gene, rmtB, thought to account for the high-level aminoglycoside resistance.

In summary, we identified a new NDM β-lactamase gene variant, blaNDM-5, encoding the fifth enzymatic variant in this rapidly emerging and troublesome family of β-lactamases. The NDM-producing isolate was recovered from a patient with a history of travel to the Indian subcontinent.

FOOTNOTES

    • Received 16 June 2011.
    • Returned for modification 20 July 2011.
    • Accepted 14 September 2011.
    • Accepted manuscript posted online 19 September 2011.
  • Copyright © 2011, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Carattoli A.,
    2. et al
    . 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63: 219–228.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Clermont O.,
    2. Bonacorsi S.,
    3. Bingen E.
    . 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66: 4555–4558.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Dallenne C.,
    2. Da Costa A.,
    3. Decre D.,
    4. Favier C.,
    5. Arlet G.
    . 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 65: 490–495.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Ellington M. J.,
    2. Kistler J.,
    3. Livermore D. M.,
    4. Woodford N.
    . 2007. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J. Antimicrob. Chemother. 59: 321–322.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Kaase M.,
    2. et al
    . 2011. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J. Antimicrob. Chemother. 66: 1260–1262.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Miriagou V.,
    2. et al
    . 2010. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin. Microbiol. Infect. 16: 112–122.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Mushtaq S.,
    2. et al
    . 2011. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother. 66: 2002–2005.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Poirel L.,
    2. Bonnin R. A.,
    3. Nordmann P.
    . 2011. Analysis of the resistome of a multidrug-resistant NDM-1-producing Escherichia coli by high-throughput genome sequencing. Antimicrob. Agents Chemother. 55: 4224–4229.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Samra Z.,
    2. et al
    . 2008. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. J. Clin. Microbiol. 46: 3110–3111.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. van der Bij A. K.,
    2. et al
    . 2011. Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob. Agents Chemother. 55: 3576–3578.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Walsh T. R.
    2010. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl. 3): S8–S14.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Yong D.,
    2. et al
    . 2009. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53: 5046–5054.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
A Novel Variant, NDM-5, of the New Delhi Metallo-β-Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom
Michael Hornsey, Lynette Phee, David W. Wareham
Antimicrobial Agents and Chemotherapy Nov 2011, 55 (12) 5952-5954; DOI: 10.1128/AAC.05108-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Variant, NDM-5, of the New Delhi Metallo-β-Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Novel Variant, NDM-5, of the New Delhi Metallo-β-Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom
Michael Hornsey, Lynette Phee, David W. Wareham
Antimicrobial Agents and Chemotherapy Nov 2011, 55 (12) 5952-5954; DOI: 10.1128/AAC.05108-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596